Latest news with #TheInsightPartners
Malaysian Reserve
2 days ago
- Automotive
- Malaysian Reserve
High-Speed Cable Market Size to Reach USD 24.99 billion in 2031, Growing at a CAGR of 10.2%,
NEW YORK, July 11, 2025 /PRNewswire/ — According to a new comprehensive report from The Insight Partners, the global high-speed cables market is observing significant growth owing to the growing deployment of data centers and rising investments in enterprise IT infrastructure. The high-speed cables market is expected to reach US$12.90 billion by 2024 from US$24.99 billion in 2031, at a CAGR of 10.2% during the forecast period 2025-2031. The demand for high-performance, reasonably priced data center interconnects has increased as cloud services grow at a never-before-seen rate. High-speed cables have become more widely used as a result of this. To explore the valuable insights in the High Speed Cables Market report, you can easily download a sample PDF of the report – High-speed cables such as DAC and AOC offer a direct physical layer connection between two ports utilizing twin-axial cables, guaranteeing signal integrity across predetermined lengths without the use of active optical components, in contrast to optical interconnects that rely on optical modules for signal conversion. The electronics, automotive, communication, and networking industries are continuously evolving by innovating their product offerings to support high speed data transfer. Thus, a rising demand for high speed cables to facilitate easy connectivity is propelling the market growth. Automotive manufacturers are installing more electronic and infotainment systems in vehicles to provide high connectivity. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the High Speed Cables are applicable in a vast array of applications that are expected to register strength during the coming years. For Detailed High-Speed Cables Market Insights, Visit: Overview of Report Findings Rising Investments in Enterprise IT Infrastructure: Rising enterprise IT infrastructure investments are directly fueling demand for high-speed interconnects such as AECs (Active Electrical Cables), AOCs (Active Optical Cables), and DACs (Direct Attach Copper). The need for quicker, more dependable, and more efficient data transfer across servers, switches, and storage systems has increased as businesses update their data centers and implement cutting-edge technologies such as edge computing, hybrid cloud, and AI/ML workloads. As businesses grow to 25G, 100G, and 400G Ethernet infrastructures, these high-speed cables are crucial for providing the low-latency and high-throughput connectivity needed by today's enterprise applications. For instance, over 40% of larger enterprises will adopt edge computing as part of their IT infrastructure by 2025, as it enables real-time analytics for smart cities, autonomous vehicles, and industrial IoT. Developments in 5G Network Services: Passive DACs, which are basically premium copper wires without any embedded electronics, are far less expensive than the cables due to these components. Advanced chipsets in AECs and VCSEL lasers in AOCs add a premium that can increase the cost by at least two to five times. DACs are frequently utilized in 5G networks for short-range connections that occur in the same area, such as O-RAN cell sites and edge data centers. These cables support high-speed data transport with low latency and power consumption. For instance, passive QSFP28 DACs are appropriate for in-cabinet direct connections since they can support 100 Gb/s, while SFP28 DACs can support 25 Gb/s. The dense cells and high traffic of 5G networks necessitate backhaul connections capable of handling hundreds of gigabits. This necessitates greater speed Ethernet connections, such as 400G or greater. DACs are essential in order to facilitate these high-speed Ethernet connections across short distances and guarantee effective data transfer between network devices. The lowest power consumption per port is also provided by passive DACs, which use between 91% and 97% less power per port than fiber cabling with independent transceivers. The volume of short-reach server network access connections quickly mounts up. Stay Updated on The Latest High Speed Cables Market Trends: Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and Asia-pacific. Asia Pacific is expected to register the highest CAGR during the forecast period. Market Segmentation Based on type, the market is segmented into DAC, PCLe, SAS, AEC, ACC, AOC, and others. The RF AOC segment held the largest market share in 2024. Based on application, the high speed cable market is segmented into switch-to-switch interconnect, switch-to-server interconnect, server-to-server interconnect, and server-to-storage interconnect. The switch to switch Interconnect segment held the largest market share in 2024. The High Speed Cables market is segmented into five major regions: North America, Europe, APAC, Middle East and Africa, and South and Central America. Competitive Strategy and Development Key Players: A few major companies operating in the high speed cables market include Amphenol Corporation, Axon Cable SAS, Molex LLC, Volex PLC, NVIDIA CORPORATION, Samtec INC, Shenzhen Sopto Technology Co., Ltd., TE Connectivity Corporation, Edge Optical Solutions, and JPC Connectivity. Trending Topics: AI-Driven Infrastructure Expansion, Advancements in High-Speed Connectivity Standards, Smart Infrastructure and IoT Integration, Automotive Data Cables, among others. Global Headlines on High Speed Cables 'Amphenol Communications Solutions (ACS) and Semtech Introduce 1.6T Active Copper Cable at OFC 2025' 'Molex Launches PCIe Cable Connection System for Open Compute Project Servers' 'Molex Launches PCIe Cable Connection System for Open Compute Project Servers' Purchase Premium Copy of Global High Speed Cables Market Size and Growth Report (2021-2031) at: Conclusion There is a high need for intra-rack and inter-rack connections in data centers. High-speed cables are ideal for these conditions as they provide fast connectivity with less than 0.1W of power usage and heat generation. The cooling demand on data center air conditioning systems is decreased by this efficiency. Furthermore, a crucial benefit of high speed cables is their longevity, which reduces the possibility of failures in high-density environments as they are less vulnerable to bending or other physical stressors. The report from The Insight Partners, therefore, provides several stakeholders—including component providers, system technology integrators, system manufacturers and others—with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. Trending Related Reports: The Medium Voltage Cable Market Size is expected to reach US$41.28 billion by 2031. Medium Voltage Cable and Accessories Market Size is expected to reach US$58.88 billion by 2031. Sewer Cable Market Size is expected to reach US$121.6 million by 2031. Wire & Cable Compounds Market is expected to register a CAGR of 8% from 2025 to 2031. Cable Modem Termination System (CMTS) Market is expected to CAGR of 8.3% from 2025 to 2031. The Medical Cables Market Size is projected to reach US$16,048.76 million by 2031. The Wire and Cable Plastics Market Size is projected to reach US$17.88 billion by 2031. The Submarine Power Cable Market Size is projected to reach US$13.45 billion by 2031. The Low Smoke Halogen Free Cable Market Size is projected to reach US$5.80 billion by 2031. The Wire and Cable Market size is projected to reach US$306.36 billion by 2031. About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us:If you have any queries about this report or if you would like further information, please contact us:Contact Person: Ankit MathurE-mail: +1-646-491-9876Press Release – Logo: View original content:
Yahoo
4 days ago
- Business
- Yahoo
Process Instrumentation Market Size to Reach USD 27.93 billion by 2031 with a 5.8% CAGR, Experiences Growth with Rising Industrial Automation Across the Globe
NEW YORK, July 9, 2025 /PRNewswire/ -- According to a comprehensive new report from The Insight Partners, the global Process Instrumentation market is observing healthy growth owing to the rising industrial automation across the globe. The Process Instrumentation market is expected to reach US$27.93 billion by 2031 from US$19.18 billion in 2024; it is expected to record a CAGR of 5.8% during the forecast period. Instrumentation aids in preventive maintenance, resolving problems before they escalate, and fine-tuning processes to improve their efficiency. Thus, the rising adoption of industrial automation drives the process instrumentation market growth. The report runs an in-depth analysis of market trends, key players, and future opportunities. Several key factors drive the Process Instrumentation market. As organizations scale operations and expand geographically, the need to manage high volumes of processes efficiently is pushing adoption of process instrumentation. To explore the valuable insights in the Process Instrumentation Market report, you can easily download a sample PDF of the report - Overview of Report Findings Rising Industrial Automation: Adoption of automation in the industrial sector is growing across the globe. Manufacturers are becoming more conscious of the major benefits associated with capital expenditure, product quality, and time to market. Industrial automation is helping manufacturers by eliminating the need for manual labor and speeding up processes. Several market players are providing industrial automation solutions, such as Mitsubishi Electric, Omron Corp., and Rockwell Automation. These players are involved in the launch of industrial automation platforms. For instance, in April 2023, Rockwell Automation, Inc. launched FactoryTalk OptiX. The FactoryTalk Optix is a contemporary cloud-enabled human-machine interface (HMI) platform that enables users to create, test, and launch apps from a web browser at any time or place. It assists clients in realizing their vision by utilizing new degrees of interconnection, scalability, and cooperation in industries. Expansion of Chemical Industry: Process instrumentation, including sensors, analyzers, and control systems, plays a key role in ensuring product quality, optimizing production processes, and complying with stringent regulatory standards. Government initiatives and investment will contribute to these sectors' growth. For instance, the Indian government's robust support for the pharmaceutical sector through initiatives such as the Production Linked Incentive (PLI) scheme, the Promotion of Research and Innovation in Pharma MedTech sector (PRIP) scheme, and the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is accelerating domestic manufacturing and innovation. This surge in production capacity and technological advancement significantly boosts the demand for process instrumentation to ensure quality control, regulatory compliance, and operational efficiency. For Detailed Process Instrumentation Market Insights, Visit: Growing Need for Efficient Energy: Rapid industrialization in Brazil, India, and China is a significant contributor to the adoption of process instrumentation. Industries such as chemicals, oil & gas, and power generation continue to be large energy consumers. As a result, countries are responding to energy efficiency programs with policies and programs to guide specific changes in energy use across sectors. For example, China's economy is energy-intensive due to a huge number of manufacturing industries. The Central Government of China has continued to develop measures to increase building energy efficiency. Energy appliance regulations and labeling, as well as energy service corporations (ESCOs), have all played crucial roles in this. China's 14th Five-Year Plan (2021–2025) contains a mandatory national target to lower energy intensity by 13.5% below 2020 levels by 2025. Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and Asia Pacific, respectively. Asia Pacific is expected to register the highest CAGR during the forecast period. Stay Updated on The Latest Process Instrumentation Market Trends: Market Segmentation Based on technology, the process instrumentation market is divided into flow meter, pressure and temperature sensor, analytical instrument, and level meter. The analytical instrument segment is anticipated to grow in the forecast period. Based on application, the process instrumentation market is divided into oil and gas, energy and power, water and wastewater, food and beverage, marine, petrochemical, chemical, and others. The energy and power segment are anticipated to grow in the forecast period. Competitive Strategy and Development Key Players: A few of the major companies operating in the Process Instrumentation market are ABB Ltd., Emerson Electric Co., Honeywell International Inc., Brooks Instrument, Schneider Electric, Siemens, Yokogawa Electric Corporation, Endress+Hauser Group Services AG, Metso Corporation, Fuji Electric Co, Ltd. Trending Topics: Industrial Automation Market, Robotic Process Automation Market, etc. Global Headlines on Process Instrumentation Market Endress+Hauser announces new compact product line for level and pressure measurement. The new compact product line from Endress+Hauser enables higher productivity, ease of use and offers optimal production scalability. The product line is specifically designed for use in the life sciences and food and beverage industries. The product line covers many hygienic applications, consisting of three measuring principles for measuring pressure, continuous levels and point levels. The new products offer optimal solutions for small vessels and a standardized and user-friendly design. Purchase Premium Copy of Global Process Instrumentation Market Size and Growth Report (2021-2031) at: Conclusion The demand for process instrumentation in Asia Pacific is primarily driven by the oil & gas and energy & power industries due to its ever-increasing population. The market is likely to record significant growth owing to increasing investments in clean energy infrastructure to meet the requirement for electricity, as well as reduce reliance on fossil fuels to generate energy. For instance, in June 2023, Latham & Watkins provided counsel to ICG, the global alternative asset manager, regarding its investment of US$ 50 million in Amp Energy India Private Ltd. (Amp India), a prominent renewable energy platform, with the potential to invest an additional US$ 50 million. This transaction represents the inaugural investment by ICG's Asia Pacific Infrastructure team, which operates across Asia and focuses on mid-market transactions, corporate-led deals, and the expansion of platforms with a strong dedication to sustainable infrastructure. This investment will facilitate Amp India's expansion strategy. ICG will collaborate closely with the company's highly skilled management team to further capitalize on the increasing demand for renewable energy in the region. With substantial government support and commitments toward decarbonization from major corporations, India's renewables market is projected to utilize 145GW over the next five years. This is anticipated to create opportunities for companies operating in the process instrumentation market to align their offerings with the goal of sustainable infrastructure and renewable energy projects in Asia Pacific. Trending Related Reports: The Ultrasonic Flow Meter Market is expected to register a CAGR of 6.4% from 2025 to 2031The Flow Meter Market is expected to register a CAGR of 5.8% from 2025 to 2031Electromagnetic Flow Meters Market Growth, Trends and Forecast by 2031Intelligent Flow Meter Market Growth, Trends, and Analysis by 2031Medical Ultrasound Flow Meter Market Share and Forecast by 2030Wireless Temperature Sensor Market Growth, Trends, and Opportunities 2031Automotive Air Conditioner Temperature Sensor Market Size Drivers, Trends, and Forecast by 2031Smart Temperature Sensors Market Growth Drivers, Trends, and Forecast by 2031Silicon Temperature Sensor Market Size, Segments, and Growth by 2031The temperature sensor market size is projected to reach US$ 9.66 billion by 2030Sound Level Meter Market Growth, Trends, and Opportunities 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us:If you have any queries about this report or if you would like further information, please contact us:Contact Person: Ankit MathurE-mail: +1-646-491-9876 Press Release: Logo - View original content to download multimedia: SOURCE The Insight Partners
Yahoo
5 days ago
- Business
- Yahoo
Colorectal Cancer Treatment Market Size is Projected to Reach USD 24.77 Billion, with a Robust 3.2% CAGR till 2031, Rising Prevalence of Cancer Boosts
NEW YORK, July 8, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global colorectal cancer treatment market is observing significant growth owing to the increasing prevalence of cancer and growing demand for rare disease diagnostic tools. The colorectal cancer treatment market is expected to reach US$24.77 billion by 2031 from US$19.93 billion in 2024, at a CAGR of 3.2% during the forecast period. Colorectal cancer, also referred to as colon cancer or bowel cancer, develops in the colon or rectum. The disease is a significant health concern, being the third most common cancer worldwide. The report runs an in-depth analysis of market trends, key players, and future opportunities. The colorectal cancer treatment market comprises a vast array of products and services that are expected to register strength during the forecast period. To explore the valuable insights in the Colorectal Cancer Treatment Market report, you can easily download a sample PDF of the report – Overview of Report Findings Increasing Burden of Colorectal Cancer: According to the World Health Organization (WHO), colon cancer is the second leading cause of cancer-related deaths worldwide. In 2022, there were over 1.9 million new colorectal cancer cases and more than 930,000 deaths due to this disease globally. Incidence rates were highest in Europe, as well as Australia and New Zealand, while mortality rates were highest in Eastern Europe. By 2040, the burden of colorectal cancer is projected to increase to 3.2 million new cases per year—a 63% rise—and to 1.6 million deaths per year, reflecting a 73% increase. The increasing prevalence of colorectal cancer is expected to drive the demand for its treatment in the coming years. Surging Advancements in Treatments and Product Approvals: The advancement and acceptance of sophisticated treatments; such as targeted therapies (e.g., cetuximab, bevacizumab, regorafenib), immunotherapies, and combination therapies; have enhanced patient outcomes and broadened treatment options. Continued research and new product approvals, including biosimilars and personalized medicine, are driving market growth. For instance, in April 2025, the Food and Drug Administration (FDA) approved the combination of two immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), for the initial treatment of some patients with advanced colorectal cancer. This approval expands the use of this immunotherapy combination into the first-line setting and can be used as the initial treatment. Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and APAC. Asia Pacific is expected to register the highest CAGR during the forecast period. For Detailed Colorectal Cancer Treatment Market Insights, Visit: Market Segmentation Based on treatment type, the colorectal cancer treatment market is segmented into surgery, chemotherapy, targeted therapy, immunotherapy, and others. In 2024, the surgery segment held the largest colorectal cancer treatment market share and is expected to register the highest CAGR during 2025–2030. By age group, the colorectal cancer treatment market is segmented into below 49 years, 50–64 years, and above 65 years. The above 65 years segment held the largest colorectal cancer treatment market share in 2024. In terms of application, the colorectal cancer treatment market is divided into preclinical drug development, biomarker analysis, translating research, and biobanking. The preclinical drug development segment held the largest share of the colorectal cancer treatment market in 2024. In terms of end user, the colorectal cancer treatment market is segmented into hospitals, specialty clinics, home care, and others. The hospitals segment held the largest share of the colorectal cancer treatment market in 2024. The colorectal cancer treatment market is segmented into five major regions: North America, Europe, APAC, Middle East and Africa, and South and Central America. Stay Updated on The Latest Colorectal Cancer Treatment Market Trends: Competitive Strategy and Development Key Players: A few major companies operating in the colorectal cancer treatment market are Champions Oncology, Inc.; Charles River Laboratories, Inc.; Crown Bioscience, Inc.; EPO Berlin-Buch GmbH; Hera BioLabs; Horizon Discovery Group plc; Oncodesign; Pharmatest Services Ltd; Urolead; and Xentech. Trending Topics: Advanced Colorectal Cancer Treatments, AI in Colorectal Cancer Treatments, Oncology PDX models, and PDX models for research, among others. Global Headlines on Colorectal Cancer Treatment Takeda Pharmaceutical announced the approval for its oral targeted therapy FRUZAQLA (fruquintinib) from the US Food and Drug Administration (FDA) to treat adults having metastatic colorectal cancer (mCRC). FRUZAQLA is the first and only selective inhibitor of all three VEGF receptor kinases approved in the US for treating mCRC previously, regardless of biomarker status. Taiho Pharmaceutical Co., Ltd. announced that the US FDA had approved LONSURF (trifluridine/tipiracil) as a single agent and in combination with bevacizumab for treating mCRC patients. These patients are previously treated with oxaliplatin-, fluoropyrimidine-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy. The Food and Drug Administration granted accelerated approval to adagrasib (Krazati) plus cetuximab developed by Mirati Therapeutics, Inc. for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Purchase Premium Copy of Global Colorectal Cancer Treatment Market Size and Growth Report (2021-2031) at: The rising prevalence of colorectal cancer and increasing innovations in cancer therapies drive the colorectal cancer treatment market growth. Colorectal cancer continues to be one of the leading causes of illness and death worldwide, with millions of new cases diagnosed each year. The increasing prevalence of CRC directly correlates with an increased demand for a wide range of treatments such as surgery, chemotherapy, targeted therapies, immunotherapy, and supportive care services. Pharmaceutical and biotech firms are investing significantly in research and development to meet unmet needs, especially for younger patients and those suffering from advanced or resistant diseases. In November 2023, Takeda received the U.S. Food and Drug Administration (FDA) approval for FRUZAQLA (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Additionally, the rise in early-onset cases is encouraging advancements in personalized medicine and less invasive surgical methods. According to an article published in White Rose in December 2024, in England, the use of minimally invasive surgery (MIS) for resections has significantly increased. For colon cancer, the percentage of resections performed using MIS increased from 34.9% in 2007 to 72.9% in 2021, while for rectal cancer it grew from 28.8% to 72.5%. Additionally, robot-assisted surgery for colon cancer increased from 0.1% in 2007 to 2.7% in 2021, and for rectal cancer from 0.2% in 2007 to 7.9% in 2021. However, there was a wide variation in the adoption of MIS at the hospital level between during 2007–2021. The report from The Insight Partners, therefore, provides several stakeholders—including PDX model developers, academic and research organizations, healthcare facilities, and others, with valuable insights to successfully navigate this evolving market landscape and unlock new opportunities. Trending Related Reports: The Kidney Cancer Therapeutics and Diagnostics Market is expected to register a CAGR of 4.9% from 2025 to 2031, The Cervical Cancer Diagnostics and Therapeutics Market is expected to register a CAGR of 4.5% from 2025 to 2031, The Ovarian Cancer Diagnostics and Therapeutics Market is expected to register a CAGR of 9.4% from 2025 to 2031 The Cancer Stem Cells Market is expected to register a CAGR of 19% from 2025 to 2031 The Cancer Therapy Market is expected to register a CAGR of 8.2% from 2025 to 2031 The Cancer Biopsies Market is expected to register a CAGR of 11.6% from 2025 to 2031 The Uterine Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 5.9% from 2025 to 2031 The Thyroid Cancer Diagnostics Market is expected to register a CAGR of 5.5% from 2025 to 2031 The Skin Cancer Diagnostics and Therapeutics Market is expected to register a CAGR of 5.6% from 2025 to 2031 The liver cancer diagnostics market size is projected to reach US$ 20.57 billion by 2031 The Pancreatic Cancer Therapy Market size is expected to reach US$ 6.47 billion by 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit MathurE-mail: +1-646-491-9876Home - Logo: View original content: SOURCE The Insight Partners Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
mRNA Sequencing Market Size to Hit USD 4.02 billion by 2031, Growing at 13.6% CAGR, Benefits from Surging Prevalence of Cancer
NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global mRNA sequencing market is observing significant growth owing to the increasing prevalence of cancer and rising demand for rare disease diagnostic tools. The mRNA sequencing market is expected to reach US$4.02 billion by 2031 from US$1.67 billion in 2024; it is expected to record a CAGR of 13.6% during the forecast period. mRNA sequencing is a technique used to analyze the complete set of mRNA molecules (transcriptome) within a cell or tissue. It provides a complete view of gene expression, including the identification of known and novel transcript isoforms, gene fusions, and allele-specific expression. With its high sensitivity and precision in quantifying gene expression, mRNA sequencing serves as a valuable resource for investigating various biological processes and disease conditions. The mRNA sequencing market analysis focuses on an array of products (instruments, consumables, etc.) and services required in various types of sequencing methods, which are expected to contribute to its strength in the coming years. The report runs an in-depth analysis of market trends, key players, and future opportunities. To explore the valuable insights in the mRNA Sequencing Market report, you can easily download a sample PDF of the report - Overview of Report Findings Increasing Prevalence of Cancer: As per the International Agency for Research on Cancer (IARC), there were ~20 million new cancer cases in 2022. By 2050, this number is predicted to increase to over 35 million new cases. Lung cancer is the most commonly occurring cancer worldwide, with 2.5 million new cases that account for 12.4% of the total new cases. Breast cancer in females ranked second (2.3 million cases, 11.6%), followed by colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). An upsurge in cancer cases has led to the higher utilization of mRNA sequencing for disease diagnosis, biomarker discovery, and therapeutic development applications. RNA sequencing allows researchers to simultaneously quantify the expression levels of thousands of genes, offering a comprehensive view of the transcriptome in both cancerous and healthy tissues. This aids in tracing the genes that are expressed differently and identifying molecular signatures linked to various cancer types, subtypes, and progression stages. By examining changes in the transcriptome, RNA sequencing assists in finding biomarkers for cancer diagnosis, prognosis, and treatment response. It also enables the detection of molecular targets for precision therapies, thus aiding in the creation of targeted treatments. For Detailed mRNA Sequencing Market Insights, Visit: Surging demand for Rare Disease Diagnostic Tools: According to the Rare Disease International alliance, more than 300 million people in the world suffer from a rare disease, and over 6,000 rare disease cases were identified as of 2023. 72% of these rare conditions are genetic. Therefore, there is a huge burden of healthcare costs associated with the treatment of rare diseases—the cost is approximately 10 times higher than the cost incurred by other diseases. For example, in the US, the cost of 373 rare diseases accounts for US$ 2.2 trillion annually. Based on estimates, the healthcare cost for all known rare diseases may be in the range of US$ 7.2–8.6 trillion annually. Thus, rare diseases associated with difficulties and delays in diagnosis, lack of treatment availability, development of new treatment, and a favorable regulatory framework and accessibility would result in the development of innovative mRNA sequencing technologies. mRNA sequencing is a powerful tool for rare disease diagnosis and research, offering insights into gene expression, alternative splicing, and the effects of mutation on gene function. Ambry Genetics' ExomeReveal test is multiomic exome sequencing, which aims to enhance rare disease detection compared to traditional DNA-based methods. This test combines Ambry's RNA analysis expertise from its hereditary cancer testing platform with its ExomeNext exome sequencing test to improve diagnostic yield for rare diseases. Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and APAC. Asia Pacific is expected to register the highest CAGR during the forecast period. Stay Updated on The Latest mRNA Sequencing Market Trends: Market Segmentation Based on type, the mRNA sequencing market is bifurcated into products and services. The products segment held a larger share of the market in 2024. In terms of method, the mRNA sequencing market is segmented into first-generation sequencing, next-generation sequencing, and third-generation sequencing. The next-generation sequencing segment held the largest share of the market in 2024. In terms of end user, the mRNA sequencing market is segmented into healthcare facilities, pharmaceutical and biotechnology companies, clinical research organizations, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2024. The mRNA sequencing market is segmented into five major regions: North America, Europe, APAC, the Middle East and Africa, and South and Central America. Competitive Strategy and Development Key Players: A few major companies operating in the mRNA sequencing market include Takara Bio Inc.; Illumina, Inc.; QIAGEN; F. Hoffmann-La Roche Ltd; Quantabio; Zymo Research Corporation; baseclick GmbH; Paragon Genomics, Inc.; Yeasen Biotechnology (Shanghai) Co., Ltd.; Novogene Co, Ltd; and Norgen Biotek Corp. Trending Topics: Advancements in mRNA sequencing, AI in next-generation sequencing, mRNA vaccines, innovative consumables used for mRNA sequencing, etc. Purchase Premium Copy of Global mRNA Sequencing Market Size and Growth Report (2021-2031) at: Global Headlines on mRNA Sequencing Roche unveiled its proprietary, breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation sequencing. Foundation Medicine, Inc., announced the US launch of FoundationOneRNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes. Lexogen unveiled the LUTHOR High-Definition Single Cell 3' mRNA-Seq Kit. The kit can detect a single gene copy within a cell, enabling researchers to get visuals of each cell's complete transcriptome, capturing 95% of expressed genes with high magnification. PacBio announced the expansion of Multiplexed Arrays Sequencing (MAS-Seq) for new assays. This assay is based on the successful "MAS-Seq" concatenation technology that enables cost-effective single-cell isoform sequencing. For More latest Life Sciences Research Reports & Industry Analysis - Conclusion The rising demand for diagnostic tools for rare diseases and cancer therapeutics propels the growth of mRNA sequencing market. Studies have shown that incorporating mRNA sequencing can increase the diagnostic rate for rare diseases by 7–36% compared to the diagnoses based on DNA sequencing alone. According to the study "Analysis of RNAseq from 4,400 individuals in the 100,000 Genomes Project identifies new potential diagnoses," published in the European Society of Human Genetics in June 2023, analysis from the 100,000 Genomes Project suggests that over 20% of individuals that remain undiagnosed under genome or exome sequencing may receive a diagnosis through mRNA sequencing. Thus, significant contributions of mRNA sequencing to disease diagnostics, drug discovery pipelines, and personalized medicine are adding to its popularity. The use of this sequencing technology is also on the rise in cancer research and tests for the diagnosis of uncommon genetic abnormalities. There has been an upsurge in the adoption of new high-throughput NGS technologies—ThermoFisher's Ion Torrent and Illumina's NovaSeq—in various applications. The report from The Insight Partners provides several stakeholders—including component providers, system technology integrators, and system manufacturers—with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. Trending Related Reports: About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us:Contact Person: Ankit MathurE-mail: +1-646-491-9876Site: Logo: View original content to download multimedia: SOURCE The Insight Partners Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Health
- Yahoo
Cervical Cancer Treatment Market Size is Expected to Reach USD 14.91 Billion by 2030, with CAGR of 5.7%, Rising Prevalence of Cervical Cancer Fuels
NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new, comprehensive report from The Insight Partners, the cervical cancer treatment market is growing significantly owing to the increasing prevalence of cervical cancer. The global cervical cancer treatment market is expected to reach USD14.91 billion by 2030 from USD10.26 billion in 2024; it is estimated to register a CAGR of 5.7% during the forecast period. Cervical cancer is a disease where abnormal cells in the cervix (the lower part of the uterus) grow out of control and may spread. The disease is often caused by a persistent infection with certain human papillomavirus (HPV). The treatment options for cervical cancer include surgery, radiation, chemotherapy, and combinations of these therapies, depending on the stage and spread of the cancer. Radiation therapy, often combined with chemotherapy, is the primary treatment for cervical cancer that has spread beyond the cervix. Surgery, such as a radical trachelectomy, may be used for localized and early-stage cancers. The report runs an in-depth analysis of market trends, key players, and future opportunities. The cervical cancer treatment market is analyzed based on type, product, and end user. To explore the valuable insights in the Cervical Cancer Treatment Market report, you can easily download a sample PDF of the report - Overview of Report Findings Increasing Prevalence of Cervical Cancer: The rising prevalence of cervical cancer is propelling the growth of the global cervical cancer treatment market. According to the World Health Organization, cervical cancer ranks as the fourth most prevalent cancer among women worldwide, with ~660,000 new cases and ~350,000 deaths reported in 2022. This surge in cases has intensified the demand for effective treatment options, encompassing surgery, radiation therapy, chemotherapy, and emerging biologic therapies. The approval of immunotherapies such as pembrolizumab (Keytruda) and tisotumab vedotin (Tivdak) has revolutionized treatment paradigms, offering new avenues for patients with advanced or recurrent cervical cancer. Furthermore, advancements in diagnostic technologies, including high-risk HPV testing and liquid-based cytology, have facilitated early detection, thereby expanding the patient pool requiring treatment. Government initiatives and increased funding for cancer research and treatment have also played a crucial role in addressing cervical cancer as a public health challenge, leading to improved access to screening and vaccination programs. These factors underscore the impact of rising cervical cancer prevalence on the expansion of the treatment market, driving innovation, accessibility, and investment in the sector. For Detailed Cervical Cancer Treatment Market Insights, Visit: Significant Investment in Research and Development (R&D): Significant investment in R&D boosts the cervical cancer treatment market growth, fueling innovation and the introduction of more effective and targeted therapies. With rising global awareness and concern for cervical cancer, particularly in low-resource settings, pharmaceutical companies and research institutions are dedicating substantial funds toward discovering novel treatments such as immunotherapies, targeted drugs, and combination therapies. FDA approval of pembrolizumab and tisotumab vedotin highlights the success of these R&D investments. Additionally, R&D has advanced diagnostic tools, such as HPV DNA testing and molecular profiling, enabling earlier detection and more personalized treatment strategies. Government funding, public-private partnerships, and nonprofit support further accelerate progress by backing clinical trials and translational research. These efforts not only expand the therapeutic pipeline but also reduce development timelines and improve treatment accessibility. By enhancing drug efficacy, safety, and cost-effectiveness, R&D investment plays a pivotal role in transforming the cervical cancer treatment landscape, addressing unmet clinical needs, and ultimately reducing global mortality rates. The ongoing commitment to R&D ensures continuous innovation, which is essential for sustaining long-term market growth and improving patient outcomes. Geographic Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and Asia Pacific. Further, Asia Pacific is expected to register the highest CAGR during the forecast period. Stay Updated on The Latest Cervical Cancer Treatment Market Trends: Market Segmentation Based on the type, the cervical cancer treatment market is segmented into squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma. The squamous cell carcinoma segment held the largest share of the market in 2024. In terms of product, the cervical cancer treatment market is categorized into surgery, radiation therapy, chemotherapy, immunotherapy, and therapeutic vaccines. The surgery segment led the market in 2024. By end user, the cervical cancer treatment market is segmented into hospitals, homecare, cancer centers, and others. The hospital segment held the largest share of the market in 2024. The cervical cancer treatment market is segmented into five major regions: North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. Competitive Strategy and Development Key Players: Major companies operating in the cervical cancer treatment market F. Hoffmann-La Roche Ltd; Merck Sharp, Dohme Corp.; GlaxoSmithKline plc.; Genentech, Inc.; Amgen Inc.; Advaxis, Inc.; Biocon; Allergan, Inc. Trending Topics: Squamous Cell Carcinoma, Adenosquamous Carcinoma, Adenocarcinoma, Radiation Therapy, Immunotherapy, Vaccines, etc. Purchase Premium Copy of Global Cervical Cancer Treatment Market Size and Growth Report (2021-2031) at: Global Headlines on Cervical Cancer Treatment Market FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer FDA Fast-Tracks Novel ADC in Cervical Cancer Conclusion The cervical cancer treatment market is experiencing steady growth driven by increasing disease prevalence, rising awareness, growing improvement in screening programs, and surging advancements in therapeutic technologies. Primarily caused by persistent infection with high-risk human papillomavirus (HPV) types, cervical cancer remains a significant public health concern, especially in low- and middle-income countries where access to preventive care such as HPV vaccination and regular Pap smears is limited. Key drivers include increased government and non-profit initiatives for cancer awareness, enhanced R&D investment, and improved diagnostic tools such as HPV DNA testing and liquid-based cytology. The market also benefits from favorable regulatory policies that fast-track approval of innovative drugs. The report from The Insight Partners provides several stakeholders—including manufacturers and end users—with valuable insights to successfully navigate this evolving market landscape and unlock new opportunities. Trending Related Reports: About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us:If you have any queries about this report or if you would like further information, please contact us:Contact Person: Ankit MathurE-mail: +1-646-491-9876 For More Life Sciences Research Reports & Industry Analysis - Logo - View original content to download multimedia: SOURCE The Insight Partners Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
